News Releases | Farapulse

FARAPULSE Pivotal Trial to Assess Its Leading Pulsed Field Ablation System for The Treatment of Atrial Fibrillation Receives FDA Conditional Approval

Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.

FARAPULSE’s Pioneering Clinical Results at HRS Link Compelling Longterm Outcomes to Established Safety and Lesion Durability Data

FARAPULSE Extensively Showcased at Leading AF Symposium

Company’s technology and clinical progress detailed across more than 12 lectures/posters

FARAPULSE featured prominently at 2019 HRS Scientific Sessions

Late Breaking Clinical Trial Presentation and concurrent JACC publication highlight FARAPULSE technology’s potential to achieve new standard of care in treating Atrial Fibrillation

FARAPULSE Receives FDA Breakthrough Designation for its Endocardial Pulsed Field Ablation System

Menlo Park, California – May 8, 2019 – FARAPULSE Inc. (“FARAPULSE” or “the “Company”) today announced it has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its Endocardial Ablation System.